Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
复制标题
DOI：
10.1016/s0041-1345(98)01361-x
复制
发表时间：
1998-12-01
影响因子：
0.9
通讯作者：
Yeldandi, V
中科院分区：
文献类型：
--
作者：
Mullen, GM;Silver, MA;Yeldandi, V
结果stable 1提供了本研究中心脏移植受者的人口学信息。有77名心脏移植受者按照我们以前的方案接受了巨细胞病毒预防（连续14天静脉注射，然后90天PO A），这些患者组成i组。另外62名接受我们最近的巨细胞病毒预防方案（连续14天静脉注射，然后90天PO G）的患者组成II组。患者性别分布相似；第一组女性22例（28.6%），男性55例（71.4%）；第二组女性15例（22.4%），男性47例（77.6%）。年龄分布相似，平均49.8岁，标准差为
RESULTSTable 1 provides the demographic information on the heart transplant recipients involved in this study. There were 77 heart transplant recipients who received CMV prophylaxis per our former protocol (sequentially 14 days of IV G followed by 90 days of PO A) and these patients comprise group I. Another 62 patients who received our more recent CMV prophylactic regimen (sequentially 14 days of IV G followed by 90 days of PO G) comprise group II. Patient gender distribution was similar; 22 (28.6%) female and 55 (71.4%) male in group I versus 15 (22.4%) female and 47 (77.6%) male in group II. Also, their age distribution was similar, with a mean of 49.8 years and standard deviation of